SCHEMBL657687

SCHEMBL657687

O=C(O)CC(CC(=O)O)c1ccc(Br)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.54
FNTB P49356 1/20 0.54
GABBR2 O75899 4/20 0.52
GABBR1 Q9UBS5 4/20 0.52
KMT2A Q03164 3/20 0.52
LMNA P02545 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP1A2 P05177 2/20 0.52
MEN1 O00255 2/20 0.52
CYP3A4 P08684 1/20 0.52
ADORA3 P0DMS8 1/20 0.52
NFKB1 P19838 1/20 0.52
DRD3 P35462 1/20 0.52
BLM P54132 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C19 P33261 1/20 0.52
THRB P10828 1/20 0.52
TSHR P16473 1/20 0.52
ITGB3 P05106 3/20 0.47
ITGAV P06756 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL657719 0.89 FNTA (0.50) FNTAFNTBGABBR2GABBR1KMT2A
SCHEMBL16249736 0.89 GABBR2 (0.61) FNTAFNTBGABBR2GABBR1KMT2A
SCHEMBL21773927 0.88 FFAR1 (0.52) FNTAFNTBGABBR2GABBR1KMT2A
SCHEMBL21773925 0.88 FFAR1 (0.52) FNTAFNTBGABBR2GABBR1KMT2A
SCHEMBL27511611 0.87 GABBR2 (0.45) FNTAFNTBGABBR2GABBR1KMT2A
SCHEMBL31339236 0.86 FNTA (0.51) FNTAFNTBGABBR2GABBR1KMT2A
SCHEMBL10523496 0.84 MIF (0.54) FNTAFNTBGABBR2GABBR1KMT2A
SCHEMBL31339242 0.83 F2 (0.46) FNTAFNTBGABBR2GABBR1KMT2A
SCHEMBL657081 0.82 ATM (0.55) FNTAFNTBGABBR2GABBR1KMT2A
SCHEMBL6180314 0.81 ESR1 (0.51) FNTAFNTBGABBR2GABBR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119841766-A Preparation method and application of glutarimide compound 上海凌凯科技股份有限公司 2025-04-18 CN claimed
WO-2026097750-A1 METHOD FOR SYNTHESIZING ARYL-SUBSTITUTED CHIRAL TETRAHYDROPYRAN RING BY MEANS OF DE-SYMMETRIZATION 杭州澳赛诺生物科技有限公司 2026-05-15 WO disclosed
CN-119841766-A Preparation method and application of glutarimide compound 上海凌凯科技股份有限公司 2025-04-18 CN disclosed
EP-4536357-A1 CYCLOPHILIN INHIBITORS AND USES THEREOF The Broad Institute, Inc. (US) 2025-04-16 EP disclosed
US-20250109165-A1 CYCLOPHILIN INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2025-04-03 US disclosed
CN-119101040-B Method for synthesizing aryl substituted chiral tetrahydropyran ring through desymmetrical synthesis 杭州澳赛诺医药技术有限公司 2025-03-21 CN disclosed
CN-119101040-A Method for synthesizing aryl substituted chiral tetrahydropyran ring through desymmetrical synthesis 杭州澳赛诺医药技术有限公司 2024-12-10 CN disclosed
WO-2024059808-A1 WEE1 INHIBITORS AND METHODS FOR TREATING CANCER RECURIUM IP HOLDINGS, LLC (US) 2024-03-21 WO disclosed
WO-2023239925-A1 CYCLOPHILIN INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2023-12-14 WO disclosed
WO-2023239925-A1 CYCLOPHILIN INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2023-12-14 WO disclosed
US-6235750-B1 NITRIC OXIDE SYNTHASE INHIBITOR PFIZER INC 2001-05-22 US disclosed
WO-2000071107-A2 NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS PFIZER PRODUCTS INC. (US) 2000-11-30 WO disclosed
US-6043284-A ACYL COENZYME A: CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS GLAXO WELLCOME INC. (US) 2000-03-28 US disclosed
WO-2000009130-A2 NEW PHARMACEUTICAL USES FOR NOS INHIBITORS PFIZER PRODUCTS INC. (US) 2000-02-24 WO disclosed
CN-1239952-A 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors PFIZER (US) 1999-12-29 CN disclosed
EP-0946512-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS PFIZER INC. (US) 1999-10-06 EP disclosed
US-5776951-A ANTICHOLESTEROL AGENT GLAXO WELLCOME INC. (US) 1998-07-07 US disclosed
WO-1998024766-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS PFIZER INC. (US) 1998-06-11 WO disclosed
EP-0706508-A1 ANTI-ATHEROSCLEROTIC DIARYL COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1996-04-17 EP disclosed
WO-1995001326-A1 ANTI-ATHEROSCLEROTIC DIARYL COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1995-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109165-A1 CYCLOPHILIN INHIBITORS AND USES THEREOF PPIF, PPID, PPIG FNTA 2903/4885FNTB 2820/4885GABBR2 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.